ahlam1399
10-01-2016, 09:54 PM
Morphosys moves closer to getting first antibody drug on market
FRANKFURT (Reuters) - German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=5gcwK2L67i8:bk8mIdh4XdY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=5gcwK2L67i8:bk8mIdh4XdY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=5gcwK2L67i8:bk8mIdh4XdY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=5gcwK2L67i8:bk8mIdh4XdY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=5gcwK2L67i8:bk8mIdh4XdY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/5gcwK2L67i8
FRANKFURT (Reuters) - German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=5gcwK2L67i8:bk8mIdh4XdY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=5gcwK2L67i8:bk8mIdh4XdY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=5gcwK2L67i8:bk8mIdh4XdY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=5gcwK2L67i8:bk8mIdh4XdY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=5gcwK2L67i8:bk8mIdh4XdY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/5gcwK2L67i8